GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Cyclically Adjusted Price-to-FCF

Aurinia Pharmaceuticals (FRA:IKAP) Cyclically Adjusted Price-to-FCF : (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aurinia Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Aurinia Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aurinia Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.119/125.4675*125.4675
=-0.119

Current CPI (Mar. 2024) = 125.4675.

Aurinia Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.099 99.473 -0.125
201409 -0.094 99.394 -0.119
201412 -0.090 98.367 -0.115
201503 -0.117 99.789 -0.147
201506 -0.103 100.500 -0.129
201509 -0.144 100.421 -0.180
201512 -0.136 99.947 -0.171
201603 -0.145 101.054 -0.180
201606 -0.138 102.002 -0.170
201609 -0.104 101.765 -0.128
201612 -0.101 101.449 -0.125
201703 -0.160 102.634 -0.196
201706 -0.150 103.029 -0.183
201709 -0.086 103.345 -0.104
201712 -0.090 103.345 -0.109
201803 -0.139 105.004 -0.166
201806 -0.125 105.557 -0.149
201809 -0.114 105.636 -0.135
201812 -0.140 105.399 -0.167
201903 -0.129 106.979 -0.151
201906 -0.128 107.690 -0.149
201909 -0.116 107.611 -0.135
201912 -0.234 107.769 -0.272
202003 -0.184 107.927 -0.214
202006 -0.179 108.401 -0.207
202009 -0.227 108.164 -0.263
202012 0.007 108.559 0.008
202103 -0.361 110.298 -0.411
202106 -0.245 111.720 -0.275
202109 -0.267 112.905 -0.297
202112 -0.174 113.774 -0.192
202203 -0.300 117.646 -0.320
202206 -0.186 120.806 -0.193
202209 -0.110 120.648 -0.114
202212 0.069 120.964 0.072
202303 -0.211 122.702 -0.216
202306 -0.020 124.203 -0.020
202309 -0.087 125.230 -0.087
202312 0.091 125.468 0.091
202403 -0.119 125.468 -0.119

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurinia Pharmaceuticals  (FRA:IKAP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines